Search Medical Condition
Please enter condition
Please choose location from dropdown

Groenkloof, Pretoria, South Africa Clinical Trials

A listing of Groenkloof, Pretoria, South Africa clinical trials actively recruiting patients volunteers.

RESULTS

Found (69) clinical trials

Trial Assessing Efficacy Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders

A study to evaluate the effect of 24 weeks of subcutaneous (SC) evolocumab compared with placebo,when added to standard of care, on percent change from baseline in lowdensity lipoprotein cholesterol (LDL-C) in pediatric subjects 10 to 17 years of age with HeFH

Phase

1.89 miles

Learn More »

Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH)

The purpose of the study is to investigate whether corifollitropin alfa (MK-8962), administered in combination with human chorionic gonadotropin (hCG), increases the testicular volume in adolescent males aged 14 to <18. In addition, the study will evaluate participants for the development of corifollitropin alfa antibodies over the course of 64 ...

Phase

1.89 miles

Learn More »

Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.

Nearly 8 000 new cervical cancer cases are diagnosed in South Africa per year; many are still undiagnosed and about 50% of diagnosed cases succumb per year. Although the current prevalence of pre-cancer cervical disease is largely unknown, data from local studies suggest regional differences and an increase in the ...

Phase N/A

1.89 miles

Learn More »

Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma

This international multi-center, randomized, controlled, open-label study will investigate the pharmacokinetics, pharmacodynamics, efficacy and safety of BCD-020 (NN: rituximab, CJSC Biocad) versus MabThera (INN: rituximab, F. Hoffmann La Roche, Ltd.) both administered as a monotherapy of patients with indolent non-Hodgkin's lymphoma. Patients will be randomized to receive 375 mg/m² BCD-020 ...

Phase

1.89 miles

Learn More »

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

This study will have a main 24-week treatment period and a 28-week extension period of treatment.

Phase

1.89 miles

Learn More »

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) plus metronidazole, compared with that of meropenem in pediatric participants with cIAI.

Phase

1.89 miles

Learn More »

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

The primary objectives of this study are to evaluate the pharmacokinetics (PK), safety, and tolerability of bezlotoxumab in children aged 1 to <18 years of age with a confirmed diagnosis of Clostridium difficile infection (CDI) who are receiving antibacterial drug treatment. The primary hypothesis is that the area under the ...

Phase

1.89 miles

Learn More »

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II IIIA or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

This is a randomized, double-blinded study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in patients with resectable Stage II, IIIA, or select IIIB nonsmall cell lung cancer (NSCLC) followed by open-label adjuvant atezolizumab or best supportive care ...

Phase

1.89 miles

Learn More »

An Investigational Immuno-therapy Trial of Nivolumab or Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum-doublet Chemotherapy Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.

Phase

2.56 miles

Learn More »

Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)

The purpose of this study is to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumors

Phase

2.56 miles

Learn More »